Statement Of Cash Flows [Abstract]

Marinomed Biotech AG - Filing #1129987

Concept	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2019-01-01 to 2019-12-31	2019-01-01 to 2019-12-31	2019-01-01 to 2019-12-31	2019-01-01 to 2019-12-31	As at 2019-12-31	As at 2018-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	6,010 EUR	—	- EUR	6,010 EUR	- EUR	- EUR	- EUR	7,216 EUR	7,216 EUR	—	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for finance costs	—	—	—	7,137,000 EUR	—	—	—	—	1,002 EUR	—	—
Adjustments for decrease (increase) in inventories	—	—	—	8,286,000 EUR	—	—	—	—	182,000 EUR	—	—
Adjustments for depreciation and amortisation expense	—	—	—	4,284,000 EUR	—	—	—	—	3,272,000 EUR	—	—
Adjustments for provisions	—	—	—	- EUR	—	—	—	—	4,530,000 EUR	—	—
Income taxes paid (refund), classified as operating activities	—	—	—	35,000 EUR	—	—	—	—	44,000 EUR	—	—
Cash flows from (used in) operating activities	—	—	—	6,885 EUR	—	—	—	—	7,641 EUR	—	—
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities	—	—	—	3,964 EUR	—	—	—	—	2,376 EUR	—	—
Cash flows from (used in) financing activities [abstract]
Payments of lease liabilities, classified as financing activities	—	—	—	787,000 EUR	—	—	—	—	984,000 EUR	—	—
Cash flows from (used in) financing activities	—	—	—	8,006 EUR	—	—	—	—	20,321 EUR	—	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	—	—	22,000 EUR	—	—	—	—	86,000 EUR	—	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	—	—	2,813 EUR	—	—	—	—	10,304 EUR	—	—
Cash and cash equivalents	—	9,207 EUR	—	—	—	—	—	—	—	12,020 EUR	1,716 EUR